From reactive healthcare to preventative health.
Our technology has an important role to play. Health systems were built around acute illness. The dominant burden is now chronic disease that develops over decades. Preventative and population health approaches aim to intervene earlier and reduce that long-term burden. This is critical in an age where the state no longer can afford the increasing financial burden of health care costs as populations age. The age of precision health care has arrived allowing us to predict, prevent, diagnose, and treat diseases more precisely.
Reactive care
- 01Disease
- 02Diagnosis
- 03Treatment
Preventative population health
- 01Risk identification
- 02Earlier intervention
- 03Nutrition, science and technology
- 04Monitoring
- 05Improved population health
Conceptual comparison of two care models. It describes a direction of travel in health policy and practice. It is not a claim about guaranteed outcomes.
Chronic disease has changed the healthcare challenge.
43 million1
DEATHS A YEAR
Noncommunicable diseases account for roughly three quarters of deaths worldwide.
2.1 billion2
PEOPLE AGED 60 AND OVER BY 2050
Longer lives extend the period in which chronic conditions develop.
17.9 million3
CARDIOVASCULAR DEATHS A YEAR
Cardiovascular disease remains the leading single cause of death.
Fragmented7
DELIVERY AND COMMISSIONING
Services are frequently funded reactively rather than as connected preventative pathways.
Related conditions, one connected challenge.
Obesity, insulin resistance, prediabetes, type 2 diabetes and hypertension are interconnected components of a growing global cardiometabolic challenge. Together they contribute substantially to cardiovascular disease and reduced healthspan.4,5,6
- Obesity + metabolic dysfunctionUPSTREAM
- Insulin resistanceMECHANISM
- Prediabetes · Type 2 diabetesOVERLAPPING
- Hypertension · Cardiovascular diseaseDOWNSTREAM
- Reduced healthspanOUTCOME
The relationships shown are interconnected, not an inevitable progression. Individual pathways vary. Nothing here is a treatment claim.
Intervene earlier.
In the established model, risk becomes disease before the system responds. A preventative model works upstream of diagnosis.
- 01
Risk identification
Recognising elevated cardiometabolic risk earlier.
- 02
Earlier intervention
Acting before conditions become established.
- 03
Ongoing support
Sustained nutrition, lifestyle and clinical input.
- 04
Monitoring
Measurement over time rather than at a single appointment.
- 05
Better management
Care organised around long-term health, not episodes.
This describes a changing healthcare paradigm. No single company delivers it. ReCocoa does not.
Population health is becoming a convergence.
Medical science increasingly sits alongside nutrition, diagnostics, monitoring, digital technology and behavioural support. The white paper cited below argues that connected approaches, rather than isolated interventions, are what improve outcomes at population scale.7 The fields below are areas of activity across the sector. They are not ReCocoa capabilities.
Population Health
- MEDICAL SCIENCE
- NUTRITION
- DIAGNOSTICS
- MONITORING
- DIGITAL TECHNOLOGY
- ARTIFICIAL INTELLIGENCE
- BEHAVIOUR AND LIFESTYLE
One technology component within a larger system.
ReCocoa has developed a flavanol technology platform. Its focus on characterised bioactive flavanols places the technology at the point where nutrition, medical foods, botanicals and health science meet.
We make no claim to prevent obesity, diabetes, hypertension or cardiovascular disease. Clinical evidence has not been established. What we can say is narrower and more useful: preventative population health will require characterised, manufacturable, evidence based components, and we are building one of them.
Any wording describing external institutional relationships is subject to approval. [CAMBRIDGE RELATIONSHIP WORDING TO BE APPROVED]
- Nutrition
- Everyday food as a route to sustained intake.
- Medical foods
- Standardised composition for defined dietary use.
- Botanicals
- Characterised plant derived bioactives.
- Health science
- Mechanistic and analytical evidence.
- Future therapeutics
- Regulated development, subject to clinical evidence.
Evidence is built with others, or not at all.
The pathway below is an intended route, not a record of achievements.
CONTRIBUTIONS
- ReCocoa technology
- University science
- Clinical research
- Population health expertise
- Public and private partners
INTENDED PATHWAY
- 01Evidence
- 02Validation
- 03Scalability
- 04Potential population impact
Validation, research and partnership will determine what this platform becomes.
We are speaking with government, universities, research institutions, funders and industrial partners about clinical validation, evaluation and scale.
Get in touchReferences
- 01World Health Organization. Noncommunicable diseases: fact sheet. WHO, 2024. Source
- 02World Health Organization. Ageing and health — fact sheet. WHO, Geneva. Source
- 03World Health Organization. Cardiovascular diseases (CVDs) — fact sheet. WHO, Geneva. Source
- 04World Health Organization. Obesity and overweight — fact sheet. WHO, 2024. Source
- 05International Diabetes Federation. IDF Diabetes Atlas, 11th edition. IDF, 2025. Source
- 06World Health Organization. Global report on hypertension: the race against a silent killer. WHO, 2023. Source
- 07White paper provided to ReCocoa. Delivering equal & effective health outcomes for society: the promise of Precision Population Health Solutions. Third-party white paper. Cited for strategic context only. It is not ReCocoa research and implies no endorsement. [SOURCE LINK TO BE CONFIRMED].